Background--Prior studies suggest that persistence with and adherence to statin therapy is low. Interventions to improve statin persistence and adherence have been developed over the past decade.
C
linical trials have shown that statins are effective in reducing the risk of coronary heart disease (CHD) events. 1, 2 Based on this evidence, the 2013 American College of Cardiology (ACC) and American Heart Association (AHA) "Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults" recommended that adults with CHD take a statin. 3 Statin therapy is also recommended for adults with other forms of atherosclerotic cardiovascular disease or LDL (low-density lipoprotein) cholesterol ≥190 mg/dL and those aged 40 to 75 years who have LDL cholesterol of 70 to 189 mg/dL in addition to diabetes mellitus or a 10-year predicted risk of atherosclerotic cardiovascular disease ≥7.5%.
3
Adults who have low adherence or who discontinue statin therapy have an increased risk of CHD events compared with their counterparts with high adherence to statins. 4, 5 Observational studies have suggested that a high proportion of adults initiating statins have low adherence or discontinue treatment. [6] [7] [8] [9] However, most large studies of statin adherence used data collected before 2005, and the use of statin therapy has increased markedly over the past 15 years. 10, 11 In addition, randomized trials have demonstrated that health system, clinician, and patient-centered approaches can improve statin adherence. [12] [13] [14] The aim of this study was to analyze trends in persistence with (ie, nondiscontinuation) and high adherence to statins among adults aged ≥21 years who initiated this medication between 2007 and 2014. Patients initiating statin therapy following a myocardial infarction (MI), those with diabetes mellitus but without a history of CHD, and those without a history of CHD or diabetes mellitus were analyzed separately because these populations have different risks of CHD events, and we hypothesized that adherence would differ among them. 15 We also determined patient characteristics associated with persistence with and high adherence to statin therapy in 2014.
Methods
We conducted a retrospective cohort study using administrative data from MarketScan (Truven Health Analytics, Ann Arbor, MI) and Medicare. The MarketScan database contains data from patients with commercial and Medicare supplemental health insurance in the United States. The institutional review board at the University of Alabama at Birmingham and the CMS approved the study and waived the requirement to obtain informed consent. Data used in the current study are available from the CMS. Other study information is available from the corresponding author.
Study Population
We identified patients in the MarketScan and Medicare databases with a statin prescription fill between January 1, 2007, and December 31, 2014 . In each calendar year between 2007 and 2014, we identified the earliest statin prescription fill for each patient (ie, their index statin fill).
From this population, we selected 3 mutually exclusive groups of patients in each calendar year: (1) patients whose index statin fill was within 30 days after hospital discharge for MI, (2) patients who had diabetes mellitus but no history of CHD, and (3) patients without a history of CHD or diabetes mellitus. MI hospitalizations and history of CHD and diabetes mellitus were defined based on previously validated algorithms and administrative claims in the year before the index statin fill, as described in Table 1 . [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] We used the 100% sample of Medicare beneficiaries with an MI to identify patients with government health insurance whose index statin fill was within 30 days following hospital discharge for MI. We used the 5% random sample of all Medicare beneficiaries to identify patients who had government health insurance with diabetes mellitus without a history of CHD and without a history of CHD or diabetes mellitus on the date of their index statin fill. All MarketScan claims were used to identify patients with commercial health insurance initiating statins following an MI, with diabetes mellitus without a history of CHD, and without a history of CHD or diabetes mellitus.
To avoid including a patient twice in the same calendar year, we excluded patients aged ≥65 years on the date of their index statin fill in the MarketScan database because this population is eligible for Medicare health insurance. Because we required a 365-day period before statin initiation to ensure that patients were not already taking a statin and to identify patient characteristics, we excluded patients aged <65 years 365 days before their index statin fill (ie, aged <66 years on their index statin fill) in the Medicare database. To ensure that the study population was composed of patients initiating statins, we excluded individuals who had a statin fill within 365 days before their index statin fill. We further restricted the analysis to patients living in the United States who had continuous inpatient, outpatient, and pharmacy coverage from 365 days before through 365 days after their index statin fill.
Clinical Perspective
What Is New?
• Persistence with statin therapy remained similar from 2007 to 2014.
• High adherence to statin therapy increased modestly among patients initiating treatment after a myocardial infarction or with diabetes mellitus between 2007 and 2014 but did not improve among those without a history of coronary heart disease or diabetes mellitus.
What Are the Clinical Implications?
• This study highlights the need to improve persistence with and adherence to statin therapy if the cardiovascular riskreduction benefits of statins demonstrated in clinical trials are to be translated into clinical practice.
• Healthcare providers should monitor statin use following initiation of treatment and work with patients to identify barriers to taking this medication with high adherence.
• Patient characteristics associated with lower persistence with and adherence to statin therapy identified in this study could be used to guide interventions aiming to increase statin persistence and adherence. 21, 22 Any of the following:
• ≥1 hospitalization with a discharge diagnosis code of atherosclerosis or thrombosis of arteries of the extremities (ICD-9-CM diagnosis code of 440. 24, 25 Any of the following:
• ≥1 hospitalization with a discharge diagnosis code of CKD (ICD-9-CM diagnosis code of 016.0, 095. Statin Use, Persistence, and Adherence
Statin use was identified using claims for pharmacy fills and included atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. The intensity of the index statin fill was defined based on the 2013 ACC/AHA cholesterol treatment guideline (Table 3) . 3 Persistence with statin therapy was defined by having at least 1 day of statin supply available to take in the last 90 days of the year following the index statin fill (ie, in the 276-365 days following initiation). To assess adherence, we calculated the Any of the following among beneficiaries without a history of stroke:
• ≥1 hospitalization with a discharge diagnosis code of stroke (ICD-9-CM discharge diagnosis code of 430. Any of the following among beneficiaries without a history of CKD:
• ≥1 hospitalization with a discharge diagnosis code of CKD (ICD-9-CM diagnosis code of 016.0, 095. Any of the following among beneficiaries without a history of dementia:
• ≥1 hospitalization with a discharge diagnosis code of dementia (ICD-9-CM diagnosis code of 331.0, 331. proportion of days covered (PDC; ie, the percentage of days on which the beneficiary had a statin available to take) in the 365 days after the index statin fill using the interval-based method. 30 Days spent in the hospital were excluded from the PDC calculation. High adherence to statin therapy was defined as PDC ≥80%.
Patient Characteristics
We used MarketScan and Medicare administrative data to determine patient age on the date of the index statin fill, sex, and race/ethnicity (which was available in Medicare only). Claims data in the 365 days before each patient's index statin fill (ie, the "look-back" period) were used to define comorbid conditions including history of CHD, diabetes mellitus, stroke, peripheral artery disease, heart failure (HF), chronic kidney disease (CKD), dementia, and depression (see "Preindex statin fill characteristics" in Table 1 ). Use of antihypertensive medication and nonstatin lipid-lowering medication was defined using claims for pharmacy fills in the look-back period. A history of low adherence to antihypertensive medication has been predictive of statin discontinuation and low statin adherence among patients initiating statin therapy following MI. 31 Consequently, we calculated the PDC for antihypertensive medication during the look-back period, with low and high adherence being defined as PDC <80% and ≥80%, respectively. Claims in the 182 days after the index statin fill were used to identify patients with a new diagnosis of CHD, diabetes mellitus, stroke, HF, CKD, or dementia and those receiving cardiologist care (see "Postindex statin fill characteristics" in Table 1 ). Pharmacy claims in the 182 days following the index statin fill were used to determine the number of medications taken by each patient. A schematic showing the timeline used to identify patient characteristics and the assessment of statin adherence is provided in Figure 1 .
Statistical Analysis
The following analyses were conducted separately in each population subgroup (ie, patients initiating statin therapy following an MI, patients with diabetes mellitus without a history of CHD, and patients without a history of CHD or diabetes mellitus Using pooled data from patients initiating a statin following an MI, patients with diabetes mellitus without a history of CHD, and patients without a history of CHD or diabetes mellitus in 2014, we analyzed characteristics associated with persistence with statin therapy, high adherence to statin therapy, and mean PDC for statins. Characteristics analyzed included age, sex, race/ethnicity, statin intensity initiated, history of diabetes mellitus, stroke, peripheral artery disease, HF, CKD, dementia, depression, use of and adherence to antihypertensive medication, and use of nonstatin lipid-lowering medication before the index statin fill. We also analyzed characteristics after the index statin fill, including a new diagnosis of CHD, diabetes mellitus, stroke, HF, CKD, or dementia; cardiologist care; and total number of medications taken. Poisson regression models with robust variance estimators were used to calculate relative risks and 95% CIs for persistence with and high adherence to statin therapy, separately, associated with patient characteristics. 32 A linear regression model was used to calculate the difference in mean PDC associated with patient characteristics. Poisson and linear regression models included adjustment for the population group (ie, patients initiating a statin following an MI, patients with diabetes mellitus without a history of CHD, and patients without a history of CHD or diabetes mellitus) and all characteristics analyzed simultaneously. All analyses were conducted using SAS 9.4 (SAS Institute) and a 2-sided level of significance <0.05.
Results

Patient Characteristics
Patients initiating a statin following an MI were older and more likely to have a history of stroke, peripheral artery disease, HF, CKD, and dementia and to be taking antihypertensive medication with high adherence before their index statin fill, compared with their counterparts with diabetes mellitus without a history of CHD and those without a history of CHD or diabetes mellitus ( Characteristics of patients initiating statin therapy in each calendar year are provided in Tables 5-7 . CHD indicates coronary heart disease; CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; MI, myocardial infarction. *Restricted to patients in Medicare. 
Factors Associated With High Statin Persistence, Adherence, and PDC in 2014
After multivariable adjustment, patients who initiated a statin following an MI were more likely to have high adherence, whereas patients with diabetes mellitus without CHD were less likely to have high adherence, each compared with their counterparts without a history of CHD or diabetes mellitus ( Figure 5 ). In addition, male sex, a history of stroke and dementia, depression, nonstatin lipid-lowering medication use before the index statin fill, a new diagnosis of CHD and diabetes mellitus, cardiologist care, and taking more medications after the index statin fill were each associated with higher likelihood of having high statin adherence. 
Discussion
Persistence with statin therapy remained similar between 2007 and 2014 among patients initiating treatment following an MI, patients with diabetes mellitus without a history of CHD, and patients without a history of CHD or diabetes mellitus. Between 2007 and 2014, high adherence to statin therapy and the mean PDC for statins increased among patients who initiated treatment following an MI and who had diabetes mellitus without a history of CHD but remained similar among patients without a history of CHD or diabetes mellitus. In 2014, only 63.8% of patients initiating a statin following an MI and <40% of those with diabetes mellitus without a history of CHD and those without a history of CHD or diabetes mellitus took this medication with high adherence. Initiating statin therapy following an MI, having a history of stroke, previously using antihypertensive medication with high adherence, and receiving cardiologist care were associated with higher statin adherence. Age <55 years, black and Hispanic versus white race/ethnicity, and prior use of antihypertensive medication with low adherence were associated with lower adherence to statin therapy following initiation.
Prior studies have suggested improvements in adherence to statin therapy following an MI over the past 25 years. 33, 34 Choudhry et al reported that high adherence to statin therapy following an MI, defined by a PDC ≥80% within 365 days after discharge, increased from 38.6% in 1995 to 56.2% in 2003 among Medicare beneficiaries with low income in CHD indicates coronary heart disease; CKD, chronic kidney disease: DM, diabetes mellitus; HF, heart failure; MI, myocardial infarction. *Limited to patients in Medicare. 34 However, these 2 prior analyses included prevalent statin users, a subgroup of patients who have been shown to have higher adherence to statins compared with new users. 35 In the current analysis of statin initiators, high adherence to statin therapy following an MI increased between 2007 and 2014. As we hypothesized, patients with diabetes mellitus without a history of CHD and patients without a history of CHD or diabetes mellitus initiating a statin had lower adherence compared with their counterparts who initiated this medication following MI. This finding may be explained by patients without a history of CHD perceiving that they have a low absolute risk for CHD events.
Results from the current analysis highlight the need to improve persistence with and adherence to statin therapy if the CHD risk reduction benefits of statins demonstrated in clinical trials are to be translated into clinical practice. In 2017, the European Society of Cardiology working group on cardiovascular pharmacotherapy published a position paper calling for comprehensive efforts to improve adherence to statin therapy in clinical practice. 36 The working group called for personalized programs to empower patients to become informed medication consumers. These programs could include interventions that have been shown to increase statin adherence in clinical trials, including regular follow-up visits, reward systems, and telephone or pharmacy reminders. [12] [13] [14] 36 The working group also highlighted the need to strengthen efforts to accurately identify patients who have adverse statin side effects and the importance of stressing the benefits of statins to overcome media stories and misperception about the safety of statins among members of the public.
In the current study, several patient characteristics were associated with lower persistence with and adherence to statin therapy. These results could be used to identify patients who are more likely to benefit from interventions that can increase statin adherence. Regular follow-up visits with healthcare professionals could improve persistence with and adherence to statin therapy because these provide an opportunity to identify reasons for low statin adherence or discontinuation, including side effects, perceived lack of benefit, and cost issues, and to reinforce the benefits of this medication for preventing CHD events. 3, [36] [37] [38] [39] Prior studies have shown that many patients who discontinue statins due to side effects can be successfully re-challenged and remain on treatment with high adherence. [40] [41] [42] Other interventions, including nurse-led cardiovascular risk factor counseling, drug-regimen simplification, reminders, and phone calls, may also be effective for increasing statin adherence. 43 Low adherence to antihypertensive medication was associated with lower persistence with and adherence to statin therapy in the current study. We analyzed adherence to antihypertensive medications because they are commonly used among US adults. 31 However, having low adherence to other medications may also be a marker for low statin persistence and adherence. Reasons for low adherence that are common among different classes of medications include cost issues, cultural beliefs and perceived lack of need of treatment in general, and fear of toxicity or adverse effects. 44 Therefore, clinicians should be aware that patients initiating statins who have low adherence to any other medication may be more likely to discontinue or to have low adherence to statin therapy. Statin discontinuation may also result from medical reasons including contraindications. 45, 46 In previous studies in the United States and Switzerland, the reason most frequently reported by patients for discontinuation of evidence-based medications for CHD including statins was physician recommendation. 47, 48 Using Medicare data, Schroeder et al reported that patients followed by cardiologists were more likely to fill a statin after an MI compared with those without cardiologist care. 49 Consistent with this finding, patients in the current analysis who received cardiologist care in the 182 days following statin initiation were more likely to take this medication with high adherence compared with their counterparts who did not receive cardiologist care. These results suggest that physician characteristics, including The current analysis has several strengths. We used data from younger patients with commercial health insurance in MarketScan and older patients with Medicare coverage, thereby providing a high degree of generalizability to US adults initiating statin therapy. In addition, the large sample size provided adequate statistical power to investigate patient characteristics associated with statin adherence. The current study also has potential limitations. Misclassification of statin use in the current analysis is possible, given that pharmacy fills indicate only whether the patient filled a prescription, not whether they took it. 50 Also, pharmacy fills in MarketScan and Medicare may not include all medications filled by patients. Therefore, the current analyses may underestimate persistence with and adherence to statin therapy if some patients paid for low-cost generic statins using a discount drug program from a major retail pharmacy chain without submitting a pharmacy claim. 51 However, we have previously reported that there is substantial agreement in lipid-lowering medication use defined by Medicare pharmacy claims and self-report or a medication inventory and that the agreement is similar for branded and generic statins. 52 Reasons for statin initiation or discontinuation are not available in the MarketScan and Medicare databases. The observational study design prevents inferring a causal association between patient characteristics and statin adherence. Given the large sample size, clinical judgment is needed when interpreting the relevance of findings that were statistically significant in the current study.
In conclusion, results from the present study indicate that persistence with and adherence to statin therapy remain low, particularly among patients initiating treatment without a history of CHD. Low persistence with and adherence to statin therapy constitute major concerns because they are associated with substantial residual risk for CHD events. Healthcare providers should monitor statin use following initiation of treatment and work with patients to identify barriers to taking this medication with high adherence.
